Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/02/22
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 02/19/18
End: 02/28/25
Due: 02/28/26
Phase: N/A
Priority: Normal
Start: 11/30/15
End: 04/30/19
Due: 04/30/20
Phase: N/A
Priority: Normal
Start: 11/16/17
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 04/30/16
End: 07/31/20
Due: 07/31/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE | NCT05492799 | Allievex Corporation | user2@example.com | None | 2022-12-02 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |
| A Treatment Extension Study of Mucopolysaccharidosis Type IIIB | NCT03784287 | Allievex Corporation | user2@example.com | None | 2018-02-19 | 2025-02-28 | 2026-02-28 | - | - | 2025-07-14 |
| A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB) | NCT02493998 | Allievex Corporation | user2@example.com | None | 2015-11-30 | 2019-04-30 | 2020-04-30 | - | - | 2025-07-14 |
| A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB) | NCT03227042 | Allievex Corporation | user2@example.com | None | 2017-11-16 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| A Treatment Study of Mucopolysaccharidosis Type IIIB | NCT02754076 | Allievex Corporation | user2@example.com | None | 2016-04-30 | 2020-07-31 | 2021-07-31 | - | - | 2025-07-14 |